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The Nup98-HoxD13 (NHD13) fusion gene was identified in a patient with therapy-related myelodysplastic
syndrome (MDS). When transgenically expressed in hematopoietic cells, mice faithfully recapitulate human
disease with serial progression from peripheral blood (PB) cytopenias and increased bone marrow (BM) blasts to
acute leukemia. It is well accepted that genomic instability in dysplastic hematopoietic stem/progenitor cells
(HSPC) drives the evolution of MDS to acute leukemia. Findings here demonstrate that reticulocytes, myeloid and
lymphoid PB cells of NHD13 mice, display an increase in the age-associated loss of glycosylphosphatidylinositol-
linked surface proteins versus wild type controls. These data correlate with a progressive increase in the DNA
damage response as measured by γ-H2AX activity, accumulating BM blasts as the disease progresses and finally
development of acute leukemia. These findings clearly demonstrate a state of progressive genomic instability that
increases the likelihood of a “second hit” or complimentary mutation later in the disease to trigger development of
acute leukemia and underscores the mechanistic nature of how the NUP98-HoxD13 transgene induces
progression of MDS to acute leukemia. Additionally, these data support the use of the PIG-A assay as an efficient,
real-time surrogate marker of the genomic instability that occurs in the MDS HSPCs.
Key Point
The PIG-A assay is a sensitive, nonlethal method for the serial assessment of genomic instability in mouse models
of MDS.
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Myelodysplastic syndrome (MDS) is a disease of the hematopoietic
stem/progenitor cell (HSPC) whose pathogenesis is closely tied to
genomic instability. A complex milieu of deficits in DNA repair,
oxidative stress, and epigenomic instability underpin the pathogenesis
of this heterogeneous disease as it evolves to acute leukemia.
Additionally, cytogenetic abnormalities are measured in the majority
of MDS patients [1], higher rates of MDS are reported in diseases
with established genomic instability, and exposures to genotoxic
agents may result in secondary MDS [2–4].
The Nup98-HoxD13 (NHD13) transgenic mouse was devel-
oped from a patient with therapy-related MDS and displays key
features of the disease with high penetrance [5]. Investigators have
hypothesized that the development of acute leukemia results from
a complimentary, pro-leukemic mutation that occurs later in the
disease course of this mouse [6]. In support of this, recent work
shows increased bone marrow (BM) γ-H2AX activity suggestinggenomic instability is an important driver of these secondary
mutations [7]. In vivo analysis of the BM HSPCs, however, is
invasive, technically challenging, and impractical for serial
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Figure 1. The NHD13 transgenic mouse develops a highly penetrant form of progressive myelodysplastic syndrome (MDS). (A) White
blood cell count (WBC) is lower in the NHD13 transgenic compared to WT controls. (B) Hemoglobin values trend downward over time
indicating progressive, age associated anemia. (C) Immature cells (blasts) within the bonemarrow, measured by side scatter vs. CD45, are
increased over WT controls at all time points and further increase with aging of the NHD13 mice. (D) NHD13 mice develop physical exam
findings consistent with MDS including pallor of the nasal region and paws. Peripheral blood is hypochromic late in the disease course.
628 PIG-A assay to measure genomic instability in MDS Byrne et al. Neoplasia Vol. 16, No. 8, 2014sampling [8,9]. As a consequence, investigators must utilize large
animal numbers that allow only a solitary, static assessment of the
BM and add expense to the study. A minimally invasive assay that
facilitates the serial measurement of genomic instability, as it
parallels the disease course, would be valuable in the study of MDS
and prediction of progression to leukemia.
In this report, we have applied testing of the phos-
phatidylinositol glycan anchor (PIG-A) gene product to the
NHD13 MDS/AML mouse model. The loss of the X-linked
PIG-A gene activity will result in the absence of glycosylpho-
sphatidylinositol (GPI)–linked proteins expressed on peripheral
blood (PB) cells and may temporally correlate with increased BM
blasts and the progression of MDS to acute leukemia. As a
potential mechanism by which the NHD13 transgene drives this
disease, we find that the loss of GPI-linked surface proteins
on PB cells was found to be closely associated with increased
γ-H2AX, a measure of the DNA damage response. These data
strongly indicate that the NHD13 transgene functions, at least in
part, by inducing a progressive form of genomic instability and
these results offer important new insight about the timing of
acquisition of leukemogenic mutations. While the results do not
identify a specific mutation that causes evolution of MDS and
acute leukemia, these data indicate that the PIG-A assayrepresents a novel, non-lethal approach for studying MDS
progression in this model.
Materials and Methods
Mice
C57BL/6 Nup98-HOXD13 (NHD13) transgenic mice were
obtained from Jackson Laboratory, (Stock # 010505, Bar Harbor,
ME) and aged alongside non-transgenic wild type (WT) littermates.
Complete blood counts were performed using a Hemavet hematology
analyzer (Drew Scientific, Waterbury, CT). Mice were housed in the
University of Florida, Cancer and Genetics Research Complex
vivarium under SPF conditions. The UF IACUC approved this study
(protocol #s 201102224 and 201203669).DNA damage assays
Assessment γ-H2AX was carried out using an established
technique [10] using P-Histone H2AX-Alexa Flour (Cell Signaling,
Danvers, MA). Samples were analyzed on an Accuri C6 flow
cytometer (BD Biosciences, San Jose, CA).
A neutral comet assay was used to measure DNA repair in HSPCs.
NHD13 and WTmice, aged 6 months, were euthanized, BM collected
from femurs and lineage (lin−) negative cells isolated by immunomagnetic
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Figure 2. The NHD13 mouse displays progressive genomic instability. (A) γ-H2AX is increased in NHD13 mice compared to controls.
(B) Representative Comet assays of Lineage-negative bonemarrow cells following irradiation with 1 Gy. (C) Following treatment with 1 Gy
ionizing radiation, the average Comet olive tail moment was calculated from 50 randomly chosen cells by Wimasis.
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1 Gy, Lin− BM cells were mixed with LM Agarose, applied to slides and
lysed at 4°C overnight (Trevigen, Gaithersburg, MD). Slides were then
electrophoresed at 21 V for 45 minutes and DNA was precipitated
followed by immersion in 70% ethanol for 30 minutes. Slides were
stained by SYBR green and observed under fluorescence microscope.
Comet analysis and Olive tail moment calculations were performed by
Wimasis Image analysis (Munich, Germany). Results represent an
average of 50 randomly chosen comets for each sample.
PIG-A Assay
Testing for GPI-linked proteins on reticulocytes was performed by
adding 2 μl of anti-CD24-FITC, 0.5 μl of anti-CD71-PE, and 1 μl
of anti-TER-119-PE-Cy5 to 37.5 μl cell staining buffer and 9 μl of
peripheral blood collected from mice (eBioscience, San Diego, CA)
[11]. For GPI-linked protein testing on monocytes and T-cells,
erythrocytes were lysed with buffer (BioLegend, San Diego, CA),
resuspended in 100 μl staining buffer, and either 1 μl F/480-FITC
and 1 μl Ly6C-PE (for monocytes) or 1 μl CD3-FITC and 1 μl
CD90-APC (for T-cells) were added. In all cases, samples were
incubated on ice for 30 minutes, washed, and resuspended. Samples
were analyzed on an Accuri C6 flow cytometer (BD Biosciences, San
Jose, CA). Up to 1 × 106 events were captured for reticulocyte analysis.
For monocytes and T-cells up to 2 × 104 events were analyzed.
Sequencing of PIG-A cDNA
CD24-negative reticulocytes were collected by sorting on a FACsAria
II at the UF ICBR Flow cytometry core. RNA was prepared fromapproximately 2000 CD24-negative reticulocytes from each mouse
using a RiboPure Blood RNA isolation kit (Life Technologies, Grand
Island, NY) and cDNA was created with a High Capacity RNA-to-
cDNA kit (Life Technologies, Grand Island, NY) according to
manufacturer protocols. As a control, cDNA was also prepared from
CD24-positive reticulocytes. A two-round, nested PCR strategy was
used to amplify and isolate the PIG-A open reading frame using the
primers and conditions described [12]. Gel isolated PCR products were
cloned into the pCR4-Topo vector by Topo-TA cloning according to
the manufacturer’s protocol (Life Technologies, Grand Island, NY).
Sanger sequencing was done at the UF ICBR using primers in flanking
the insert and internal primers previously described [12]. Mutations
were identified by comparing the sequence of individual clones to WT
using CLC sequence viewer 7.0.2 software (CLCbio, Boston, MA).
Results
In the disease paroxysmal nocturnal hemoglobinuria, hemolytic
manifestations arise from an acquired somatic mutation of the X-
linked PIG-A gene [13]. The loss of this gene product results from a
spontaneous mutation of the HSPC which is subsequently observed
in its progeny circulating in the PB [14]. As the result of the
mutational inactivation of PIG-A, affected erythrocytes that arise
from the affected BM HSPC do not express necessary GPI-linked
complement regulatory proteins (CD55 and CD59) which renders
them susceptible to clinically significant complement mediated
hemolysis. We hypothesize that this association will also be present
and can be detected in the terminally differentiated PB cell progeny of
such affected MDS BM HSPCs.
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Figure 3. Evaluation of PIG-A loss in peripheral blood cells to measure genomic instability. (A) Experimental design for measuring PIG-A
cDNA mutations and loss of GPI-linked proteins. (B) Typical flow cytometry gates and graphs to enumerate CD24-deficient reticulocytes
detected in the CD24-CD71+Ter119+ quadrant of peripheral blood. (C) Schematic of the mouse PIG-A cDNA amplification and
sequencing strategy.
630 PIG-A assay to measure genomic instability in MDS Byrne et al. Neoplasia Vol. 16, No. 8, 2014To study any progressive nature of genomic instability over the
natural history of MDS, we selected the Nup98-HOXD13
(NHD13) transgenic mouse model of human MDS. This mouse
model demonstrates the key clinical characteristics of MDS with
evolution to acute leukemia as observed in the PB and BM of humans
with this disease [5]. The mice develop leukopenia early in life as
evidenced by significantly reduced white blood cell counts (WBC)
compared to WT mice (Figure 1A, P b .01). In addition, NHD13
mice display a progressive macrocytic anemia characterized by a trend
of decreasing hemoglobin concentration as mice age (Figure 1B).
Following this, NHD13 mice display a significant, serial increase of
BM blasts upon aging that precede the development of acute
leukemia (Figure 1C, P b .01). In addition, NHD13 mice develop a
characteristic anemic phenotype with noticeable pallor of their fore-
and hind limbs and of the nasal region (Figure 1D). Late in the disease
course, the PB of NHD13 mice becomes hypochromic and
noticeable weight loss occurs (Figure 1D and data not shown).
To measure progressive genomic instability that may occur in
NHD13 mice as they age, we first evaluated γ-H2AX activity in PBmononuclear cells (PBMCs) to detect activation of the DNA damage
response that may occur due to increased genomic instability.
Significantly, at 6 months of age γ-H2AX activity is increased by
almost 5 fold in PBMCs of NHD13 mice compared to WT controls
(Figure 2A, P b .01). Furthermore, both NHD13 and WT mice,
display a progressive age-associated increase of γ-H2AX in PBMCs
(Figure 2A). Second, we determined whether any such increased
genomic instability observed in cells from NHD13 mice may be due
to failure of DNA repair in HSPCs. For this, the lineage-negative
HSPC BM population was isolated from WT and NHD13 mice and
a Neutral Comet assay was performed to measure the extent and rate
of DNA double-strand break repair following irradiation of these cells
with 1 Gy (Figure 2B). The repair of double-strand breaks was
quantified by measuring the Comet Olive Tail Moment (OTM) for
50 randomly chosen cells (Comets) in each sample. Significantly, at
1 hour following irradiation, HSPCs from NHD13 mice display a
significant increase in the average OTM compared to cells from WT
mice, indicating that NHD13 HSPCs are more susceptible to DNA
damage (Figure 2C, 131 vs. 83, P b .01). Furthermore, 24 hours
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Figure 4. Frequency of GPI-linked protein loss progresses with age and correlates with disease phenotype. (A) Absolute number of
CD24-negative reticulocytes is increased in PB of NHD13mice compared toWTmice and increases with age. 1 × 106 cells were analyzed
for each sample. (B) Frequency of CD24 loss (CD24 mutants/total reticulocytes x 100) increases with age. (C) In PB of NHD13 mice
CD90-negative T-cells increase with age and are increased compared to WT controls. 2 × 104 events were analyzed. (D) Loss of the
monocyte GPI-linked protein Ly-6C increases over disease course in NHD13 mice. 2 × 104 events were analyzed.
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mice display an increased number of Comet cells with an increased
OTM compared to cells from WT mice (Figure 2, B and C). Taken
together these results suggest that the progressive genomic instability
observed in the NHD13 model may be due to failure of DNA repair
in HSPCs from transgenic mice and may explain why leukemogenic
mutations are serial and accumulate with time to herald disease
progression [6,7].
As an efficient, real-time means to measure genomic instability of
the MDS mouse in vivo, a flow cytometry assay was used to serially
measure spontaneous mutations of the X-linked phosphatidylinositol
glycan anchor (PIG-A) gene that results in the absence of
glycosylphosphatidylinositol (GPI)-linked anchor proteins on surface
of peripheral blood cells (Figure 3) [11,15]. We first measured loss of
the GPI-linked protein CD24 on the surface of peripheral
reticulocytes since these cells are abundant and easily collected from
mice without the need for euthanasia. In addition, due to their short
lifespan (48–72 hours), reticulocytes are an attractive surrogate for the
real-time measurement of HSPC genomic instability, since mutations
observed over serial measurements may represent mutations occurring
in the HSPC population(s) that constantly replenishes these cells
[12,16]. When compared to WT, NHD13 mice have a significantly
higher number of PB reticulocytes on which the GPI-linked protein
CD24 is absent (Figure 4A; 1072 vs 20 per 2 × 105 reticulocytes at
8 months, P b .05). To account for any variability of reticulocytosis, a
mutation frequency was calculated by dividing the number ofCD24-negative reticulocytes by the total number of reticulocytes.
Importantly, the frequency of CD24 negative cells significantly
increases as NHD13 mice age (Figure 4B). Second, we also evaluated
other PB cells that arise from the myeloid or lymphoid lineage to
confirm that the loss of GPI-linked proteins was universal among PB
circulating cells and therefore likely due to mutation of PIG-A in
HSPCs. We tested for loss of Ly6C on monocytes (granulocyte-
monocyte progenitor) and CD90 on T-cells (common lymphoid
progenitor). Similar to reticulocytes, NHD13 mice have approxi-
mately twice the frequency of somatic mutations in T-cells and
monocytes compared to WT control cells (Figure 4, C and D). While
the differences in T-cells was significant, due to the low numbers of
monocytes available for analysis in the PB sample collected from a
cheek bleed and the low frequency of Ly6C-negative cells, the
differences between the NHD13 and WT, although showing a trend,
did not reach statistical significance. Collectively, these results
strongly suggest that the loss of GPI-linked proteins on PB cells
represents a mutation at the level of the HSPC.
In order to confirm that any loss of CD24 was due to a mutation in
the PIG-A gene, the PIG-A cDNA from CD24-negative reticulocytes
sorted from the PB of three 8-month-old NHD13 mice was amplified
and sequenced (Figure 3). Four PIG-A cDNA clones were analyzed
from the CD24-negative reticulocytes of each mouse. As a control,
PIG-A cDNA was also amplified from CD24-positive reticulocytes of
each mouse. All four CD24-negative clones from each of the three
mice contained mutations in the PIG-A cDNA sequence (Table 1).
Table 1. Mutations in the PIG-A open reading frame of CD24-negative reticulocytes.
Mouse Clone cDNA position a (exon) Mutation b Consequence
1 A 307 (exon 2) G to A Gly-64 to Arg
802 (exon 2) T to C Val-229 to Ala
1191 (exon 5) G to A Gly-359 to Ser
1385 (exon 6) T to C Silent
1490 (exon 6) T to C Silent
1509 (exon 6) T to C Trp-465 to Arg
1555 (exon 6) A to G Lys-480 to Arg
B 710 (exon 2) G to T Silent
914 (exon 3) deletion of A Frameshift
1191 (exon 5) G to A Gly-359 to Ser
1531 (exon 6) A to G Asp-427 to Gly
C 155 (exon 2) T to C Silent
767 (exon 2) A to G Silent
1021 (exon 4) A to G Gln-302 to Arg
1104 (exon 5) G to C Val-330 to Leu
1269 (exon 6) T to C Phe-385 to Leu
D 756 (exon 2) G to A Asp-214 to Asn
1191 (exon 5) G to A Gly-359 to Ser
2 A 227 (exon 2) G to A Met-37 to Ile
235 (exon 2) A to G Asp-40 to Gly
722 (exon 2) A to G Ile-202 to Met
742 (exon 2) C to T Ala-209 to Val
1270 (exon 5) T to C Phe-385 to Ser
B 328 (exon 2) C to T Thr-71 to Ile
527 (exon2) deletion of T Frameshift
992 (exon 4) A to G Silent
1253 (exon 5) C to t Silent
C 537 (exon 2) C to T Silent
542 (exon 2) C to T His-141 to Tyr
D 1389 (exon 6) A to G Thr-425 to Ala
3 A 301 (exon 2) A to G Glu-62 to Gly
571 (exon 2) C to T Thr-152 to Ile
660 (exon 2) A to G Ile-182 to Val
1335 (exon 6) A to G Silent
B 301 (exon 2) A to G Glu-62 to Gly
571 (exon 2) C to T Thr-152 to Ile
660 (exon 2) A to G Ile-182 to Val
1335 (exon 6) A to G Silent
C 301 (exon 2) A to G Glu-62 to Gly
571 (exon 2) C to T Thr-152 to Ile
660 (exon 2) A to G Ile-182 to Val
1335 (exon 6) A to G Silent
D 301 (exon 2) A to G Glu-62 to Gly
571 (exon 2) C to T Thr-152 to Ile
660 (exon 2) A to G Ile-182 to Val
1335 (exon 6) A to G Silent
a The nucleotide position is based on the numbering of the mouse PIG-A cDNA sequence
(Genbank NM_011081).
b Sequence alterations in the nontranscribed cDNA strand compared to WT PIG-A.
632 PIG-A assay to measure genomic instability in MDS Byrne et al. Neoplasia Vol. 16, No. 8, 2014Most of the mutations were single base pair substitutions resulting in
amino acid replacement. However, two mice had clones that had a
nucleotide deletion resulting in a frameshift mutation (Table 1).
Significantly, 3 of 4 separate clones from mouse 1 carried the same
mutation at nucleotide 1191 and all 4 clones of mouse 3 had identical
PIG-A mutations. These identical mutations may be due to
expansion of PIG-A mutations in HSPCs while non-identical
mutations likely arise in lineage committed cells. Importantly, PIG-
A cDNA from all of the CD24-positive reticulocytes sequenced as
WT PIG-A (data not shown). These data demonstrate that the PIG-A
mutant phenotype detected in PB reticulocytes by loss of CD24 is
caused by mutation of the PIG-A gene.
Discussion
In MDS, genomic instability is a complex and multifactorial process
with microsatellite instability and aberrant DNA repair [4,17,18].Specifically, reduced expression of non-homologous end joining
DNA repair genes in the NHD13 model may promote genomic
instability and increase translocation frequency [18,19]. Additionally,
it is clear that point mutations, alterations in telomere regulation, and
epigenetic changes can all contribute to genomic instability in both
the NHD13 model and MDS patient samples [20–22]. These
genotoxic influences appear to intensify with aging and can result in
the loss of important tumor suppressor genes or activation of an
oncogene to drive leukemia. Here we report that the loss of the PIG-A
phenotype with age mirrors the age associated increases of both
γ-H2AX and BM blasts in the NHD13 mice that precedes evolution
of MDS to acute leukemia. We recognize that the loss of GPI-linked
proteins in MDS is unlikely to be the catalyst for the progression to
frank leukemia. Instead, we propose that the increased rate of GPI-
linked protein loss in the PB cells, which correlates with disease-
specific findings of the PB and BM, is indicative of the progressive
genomic instability inherent to this disease. Thus, the strength of the
PIG-A assay is its ability to allow the non-lethal, serial measurements
of genomic instability that may be representative of any gene at the
level of the MDS HSPC.
Future directions stemming from these findings may involve use of
the PIG-A assay to: 1) discriminate mice that will develop acute
leukemia in the NHD13 background; 2) evaluate genomic instability
in other animal BM failure/hematologic malignancy models; and
3) perform serial measurements of genomic instability in patients with
MDS that are at risk of developing acute leukemia.
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